Drugs / CORETOX®
CORETOX®
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05164003 | Jul → Sep 2017 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT03796351 | Sep 2012 → Jan 2013 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03289702 | Nov 2017 → Jun 2018 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT03908008 | Jan → May 2014 | — | Medy-Tox | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coretox | “To compare the efficacy and safety of MT10107 (Coretox) with those of onabotulinum toxin A (Botox) in patients with poststroke upper limb spasticity” PMID 32497599 ↗ Jun 2020 |
| Known as | Botulinum toxin type A | “MT10107 (Botulinum toxin type A)” NCT03908008 ↗ |
| Known as | MT10107 | “To compare the efficacy and safety of MT10107 (Coretox) with those of onabotulinum toxin A (Botox) in patients with poststroke upper limb spasticity” PMID 32497599 ↗ Jun 2020 |
| Modality | Protein / enzyme biologic | “MT10107(botulinum toxin type A)” NCT03796351 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT03796351 ↗ |